brimonidine tartrate has been researched along with Facial Dermatoses in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahlin, J; Sukakul, T; Svedman, C | 1 |
| Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Kim, JM; Kwon, HJ; Lee, SJ; Park, KY | 1 |
| Kumarasinghe, SP; Yap, FHX | 1 |
| Kim, H; Kim, HS; Lee, SJ | 1 |
| Bonamonte, D; Filoni, A; Giudice, G; Vestita, M | 1 |
| Arents, BWM; Carter, B; Charland, L; Fedorowicz, Z; Tan, J; van der Linden, MMD; van Zuuren, EJ | 1 |
| Fowler, J; Jackson, M; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M | 1 |
| Benkali, K; Bouer, R; Fernando, A; Graeber, M; Leoni, M; Rony, F; Wagner, N | 1 |
| Collgros, H; Lamas-Doménech, N | 1 |
| Rajagopalan, A; Rajagopalan, B | 1 |
| Leoni, M; Tan, J | 1 |
| Bewley, AP; Hofmann, MA; Homey, B; Kerrouche, N; Layton, AM; Lehmann, P; Ma, YM; Nohlgård, C; Sarwer, DB; Schaller, M | 1 |
| Gerber, PA | 1 |
| Cookson, H; McFadden, J; White, IR; White, J | 1 |
| Bangsgaard, N; Fischer, LA; Zachariae, C | 1 |
| Fowler, JF | 1 |
| Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M | 1 |
| Ratan, J; Sodhi, PK; Verma, L | 1 |
| Brodsky, MC; Scruggs, JT; Whiteside-Michel, J | 1 |
2 review(s) available for brimonidine tartrate and Facial Dermatoses
| Article | Year |
|---|---|
Topical Brimonidine Tartrate 0.33% Gel on Postlaser Erythema: Our Experience and Review of the Literature.
Topics: Brimonidine Tartrate; Erythema; Facial Dermatoses; Female; Gels; Humans; Laser Therapy; Male; Middle Aged; Vasoconstrictor Agents; Young Adult | 2018 |
Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Brimonidine Tartrate; Combined Modality Therapy; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Evidence-Based Medicine; Facial Dermatoses; Humans; Intense Pulsed Light Therapy; Low-Level Light Therapy; Oxymetazoline; Randomized Controlled Trials as Topic; Rosacea; Severity of Illness Index; Treatment Outcome | 2019 |
5 trial(s) available for brimonidine tartrate and Facial Dermatoses
| Article | Year |
|---|---|
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Area Under Curve; Biological Availability; Brimonidine Tartrate; Drug Administration Schedule; Facial Dermatoses; Female; Gels; Humans; Male; Ophthalmic Solutions; Quinoxalines; Rosacea | 2014 |
Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Diagnostic Self Evaluation; Double-Blind Method; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Reproducibility of Results; Rosacea; Severity of Illness Index; Young Adult | 2015 |
Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Patient Satisfaction; Rosacea; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2015 |
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult | 2012 |
13 other study(ies) available for brimonidine tartrate and Facial Dermatoses
| Article | Year |
|---|---|
Primum non nocere; the importance of evaluating the effect of treatment and considering side effects.
Topics: Anti-Inflammatory Agents; Brimonidine Tartrate; Budesonide; Dermatologic Agents; Diagnosis, Differential; Erythema; Facial Dermatoses; Humans; Hydrocortisone; Male; Middle Aged; Patch Tests; Rosacea | 2021 |
Periocular allergic contact dermatitis caused by brinzolamide.
Topics: Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Dermatitis, Allergic Contact; Drug Combinations; Facial Dermatoses; Female; Glaucoma; Humans; Middle Aged; Ophthalmic Solutions; Sulfonamides; Thiazines | 2021 |
Topical brimonidine gel for extended-duration local anaesthesia.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthesia, Local; Anesthetics, Local; Brimonidine Tartrate; Erythema; Facial Dermatoses; Gels; Humans; Intense Pulsed Light Therapy; Lentigo; Lidocaine; Male; Middle Aged; Pain, Procedural; Time Factors | 2018 |
Brimonidine for treatment of telangiectasia of dermatomyositis.
Topics: Administration, Topical; Adult; Brimonidine Tartrate; Dermatomyositis; Facial Dermatoses; Female; Gels; Humans; Quality of Life; Severity of Illness Index; Telangiectasis; Treatment Outcome | 2018 |
Image Gallery: Brimonidine gel for facial erythema in Netherton syndrome.
Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Dermatologic Agents; Erythema; Facial Dermatoses; Female; Gels; Humans; Netherton Syndrome; Off-Label Use | 2018 |
Facial erythema: keys to the differential diagnosis.
Topics: Alcohol Drinking; Biomarkers; Brimonidine Tartrate; Diagnosis, Differential; Emotions; Endocrine System Diseases; Erythema; Facial Dermatoses; Flushing; Humans; Neoplasms; Symptom Assessment | 2015 |
Allergic contact dermatitis to topical brimonidine.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatitis, Allergic Contact; Drug Eruptions; Erythema; Facial Dermatoses; Humans; Male; Middle Aged | 2015 |
Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Drug Eruptions; Erythema; Facial Dermatoses; Gels; Humans; Male; Photochemotherapy; Rosacea; Sunlight | 2016 |
Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatitis, Allergic Contact; Dermatologic Agents; Facial Dermatoses; Female; Gels; Humans; Rosacea; Young Adult | 2015 |
Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Dermatitis, Allergic Contact; Facial Dermatoses; Humans; Male; Middle Aged; Rosacea | 2016 |
Facial Dermatitis and Rosacea.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Antimicrobial Cationic Peptides; Antiparasitic Agents; Brimonidine Tartrate; Cathelicidins; Dermatitis; Dermatologic Agents; Dicarboxylic Acids; Facial Dermatoses; Humans; Ivermectin; Rosacea | 2016 |
Dermatological side effects of brimonidine: a report of three cases.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Dermatitis, Allergic Contact; Diagnosis, Differential; Facial Dermatoses; Female; Glaucoma, Open-Angle; Humans; Lichen Planus; Male; Nail Diseases; Ocular Hypertension; Ophthalmic Solutions; Patch Tests; Quinoxalines | 2003 |
The teardrop sign: a rare dermatological reaction to brimonidine.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Drug Eruptions; Facial Dermatoses; Humans; Male; Quinoxalines | 2000 |